CorMedix Inc (NYSEAMERICAN:CRMD) Unveils Its Second Quarter Financial Results

0
1206

CorMedix Inc (NYSEAMERICAN:CRMD) is a biopharmaceutical company that focuses on the manufacture of therapeutic products. These products play a major role in the treatment and prevention of inflammatory and infectious diseases.

A close outlook

This business guru unveiled the financial results for the second quarter and still went ahead to give an update on the latest business undertakings.

The Chief Executive Officer of CorMedix Khoso Baluch opined, “We were thrilled to have recently announced the best-case scenario outcome for our LOCK-IT-100 interim analysis, with the Data Safety Monitoring Board recommending the trial be halted for efficacy and data submitted to the FDA.”

Baluch went further to outline that the company’s clinical team directed a huge deal of effort towards the locking of the interim data set.

Future plans

Baluch applauded the remarkable results and wishes the company well as it embarks on completing the latest trial. From that point the company will get in touch with the FDA. The company’s objective is to formulate the next move in line with the Neutrolin development plan. Upon reaching an agreement with the FDA, the business guru will plan on the way forward.

This official believes Neutrolin has all it takes to enhance patient care in a meaningful way. The various costly and potentially deadly catheter-related bloodstream infections make life unbearable for quite a significant number of people. Eliminating these is important and the company says  it has the data validating Neutrolin’s efficacy at hand.

Baluch says it is a good thing that they have with them enough capital that will steer them beyond the FDA meeting. Later on, they intend undertake an evaluation of the company’s options and capital needs in a bid to get to the NDA filing.

CorMedix Inc also applauded FDA’s latest move. The body agreed to the company’s request to regain compliance with its continued listing standards. The body gives the company a plan period through December the following year.

In the course of the plan period, the company will try to conform to the set standards to avoid chances of getting delisted.

This report is for information purposes only, and is neither a solicitation or recommendation to buy nor an offer to sell securities. Financials Trend is not-a-registered-investment-advisor. Financials Trend is not a broker-dealer. Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. Financials Trend accepts no liability for any losses arising from an investor's reliance on the use of this material. Financials Trend sometimes gets compensated up to one hundred and fifty thousand dollars per month for featuring particular stocks. See site disclaimer for complete compensation. Financials Trend and its affiliates or officers currently hold no shares of these stocks. Financials Trend and its affiliates or officers will purchase and sell shares of common stock of these stocks, in the open market at any time without notice. Financials Trend will not update its purchases and sales of these stocks in any future postings on Financials Trend's websites. Certain information included herein is forward-looking within the context of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. The words "may", "would," "will," "expect," "estimate," "anticipate," "believe," "intend," " project," and similar expressions and variations thereof are intended to identify for ward-looking statements. Such forward- looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. *Financials Trend does not set price targets on securities. Never invest into a stock discussed on this web site or in this email alert unless you can afford to lose your entire investment.